# A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

> **NCT05556200** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 58 (estimated)

## Conditions studied

- Breast Cancer
- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Anti-PD-1 monoclonal antibody
- **DRUG:** VEGFR2 Tyrosine Kinase Inhibitor

## Key facts

- **NCT ID:** NCT05556200
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05556200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05556200, "A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05556200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*